Evotec AG

Joern Aldag will resign from his position as president & chief executive officer of Evotec, effective December 31, 2008. Dr. Mario Polywka, chief operating officer, and Dr. Klaus Maleck, chief financial officer, will jointly lead the Company until a permanent successor is announced.

Dr. Flemming Ornskov, Evotec’s chairman, said, “During his 11-year tenure, Joern Aldag played a pivotal role in the transformation of Evotec from a technology provider to an integrated, CNS-focused biopharmaceutical company. Today the company has a very strong financial position and a deep preclinical and clinical pipeline of CNS drug candidates that provide a strong basis for future success. On behalf of the Evotec board, I would like to thank Joern Aldag for his effective and very successful leadership of the Company and we wish him ongoing success for his future endeavors.”